Amyloid-β Clearance Mechanisms in Alzheimer's Disease
ConditionAlzheimer's Disease (AD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-85
SponsorLudwig-Maximilians - University of Munich
About this trial
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
Eligibility criteria
Qualifiers
Diagnosis of amnestic MCI or AD dementia or clinical normal
Able to provide written informed consent
Unchanged pharmacotherapy within 4 days prior to the study specific assessments
Fluent in German
Disqualifiers
Unable to give informed consent or has a legal guardian
Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
Clinically relevant depression
Acute suicidality
Trial design
Treatments tested in this trial
- positron emission tomography (PET)
Treatment groups
60 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov